Jason Bednar
Stock Analyst at Piper Sandler
(2.19)
# 2,891
Out of 5,090 analysts
190
Total ratings
40.97%
Success rate
-4.21%
Average return
Main Sectors:
Stocks Rated by Jason Bednar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COO The Cooper Companies | Reiterates: Overweight | $83 → $94 | $82.27 | +14.26% | 15 | Dec 5, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Neutral | $200 → $190 | $195.27 | -2.70% | 11 | Nov 7, 2025 | |
| ICUI ICU Medical | Maintains: Overweight | $153 → $172 | $141.69 | +21.39% | 3 | Nov 7, 2025 | |
| SOLV Solventum | Maintains: Overweight | $94 → $98 | $85.32 | +14.87% | 8 | Nov 7, 2025 | |
| SHC Sotera Health Company | Maintains: Neutral | $15 → $17 | $16.57 | +2.60% | 3 | Nov 5, 2025 | |
| MMSI Merit Medical Systems | Reiterates: Overweight | $105 → $109 | $84.24 | +29.39% | 14 | Oct 31, 2025 | |
| ALGN Align Technology | Reiterates: Overweight | $190 → $200 | $158.16 | +26.45% | 32 | Oct 30, 2025 | |
| MASI Masimo | Maintains: Overweight | $200 → $210 | $143.34 | +46.50% | 16 | Aug 6, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $17 → $19 | $20.28 | -6.31% | 13 | Aug 1, 2025 | |
| LUNG Pulmonx | Downgrades: Neutral | $9 → $2.5 | $2.05 | +22.25% | 12 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $11.82 | +187.65% | 11 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4.5 → $3.5 | $5.66 | -38.16% | 7 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $16 | $11.32 | +41.34% | 8 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $77 | $73.59 | +4.63% | 7 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4.5 | $2.33 | +93.55% | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $265 | $263.23 | +0.67% | 9 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $6 | $3.62 | +65.75% | 5 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $3.90 | +79.49% | 5 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $20 | $1.23 | +1,526.02% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $372 | $572.05 | -34.97% | 4 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $95 | $84.14 | +12.91% | 1 | Apr 19, 2023 |
The Cooper Companies
Dec 5, 2025
Reiterates: Overweight
Price Target: $83 → $94
Current: $82.27
Upside: +14.26%
Becton, Dickinson and Company
Nov 7, 2025
Maintains: Neutral
Price Target: $200 → $190
Current: $195.27
Upside: -2.70%
ICU Medical
Nov 7, 2025
Maintains: Overweight
Price Target: $153 → $172
Current: $141.69
Upside: +21.39%
Solventum
Nov 7, 2025
Maintains: Overweight
Price Target: $94 → $98
Current: $85.32
Upside: +14.87%
Sotera Health Company
Nov 5, 2025
Maintains: Neutral
Price Target: $15 → $17
Current: $16.57
Upside: +2.60%
Merit Medical Systems
Oct 31, 2025
Reiterates: Overweight
Price Target: $105 → $109
Current: $84.24
Upside: +29.39%
Align Technology
Oct 30, 2025
Reiterates: Overweight
Price Target: $190 → $200
Current: $158.16
Upside: +26.45%
Masimo
Aug 6, 2025
Maintains: Overweight
Price Target: $200 → $210
Current: $143.34
Upside: +46.50%
Envista Holdings
Aug 1, 2025
Maintains: Neutral
Price Target: $17 → $19
Current: $20.28
Upside: -6.31%
Pulmonx
Jul 31, 2025
Downgrades: Neutral
Price Target: $9 → $2.5
Current: $2.05
Upside: +22.25%
Jun 27, 2025
Reiterates: Overweight
Price Target: $34
Current: $11.82
Upside: +187.65%
May 8, 2025
Maintains: Neutral
Price Target: $4.5 → $3.5
Current: $5.66
Upside: -38.16%
Apr 30, 2025
Maintains: Neutral
Price Target: $20 → $16
Current: $11.32
Upside: +41.34%
Apr 30, 2025
Maintains: Overweight
Price Target: $83 → $77
Current: $73.59
Upside: +4.63%
Mar 28, 2025
Maintains: Overweight
Price Target: $5 → $4.5
Current: $2.33
Upside: +93.55%
Feb 3, 2025
Maintains: Overweight
Price Target: $260 → $265
Current: $263.23
Upside: +0.67%
Nov 7, 2024
Maintains: Overweight
Price Target: $8 → $6
Current: $3.62
Upside: +65.75%
Aug 15, 2024
Reiterates: Overweight
Price Target: $7
Current: $3.90
Upside: +79.49%
Aug 7, 2024
Maintains: Overweight
Price Target: $70 → $20
Current: $1.23
Upside: +1,526.02%
Jan 3, 2024
Maintains: Outperform
Price Target: $310 → $372
Current: $572.05
Upside: -34.97%
Apr 19, 2023
Initiates: Overweight
Price Target: $95
Current: $84.14
Upside: +12.91%